



## Imugene allowed European patent for novel drug delivery technology

---

### Highlights

- European Patent Office has issued an Intention to Grant Communication for Imugene's patent application protecting its Linguet™ drug delivery technology
- Patent protects specific drug formulations targeting bone loss prevention

**Melbourne, 27 September 2013:** Australian drug delivery technology company Imugene (ASX:IMU) has announced today that the European Patent Office has issued an Intention to Grant Communication for the Company's novel drug delivery technology Linguet™ (patent no: 06721354.6).

The European patent provides protection around Linguet's™ formulations and other specific excipients for a class of drugs that prevent the loss of bone mass, known as bisphosphonic acids and bisphosphonates, which are used to treat conditions such as osteoporosis and multiple myeloma.

Linguet is now protected by the same patent in three key markets including Europe, Japan and China.

Imugene uses its proprietary drug delivery technology to improve the efficacy and safety of a diverse number of existing prescription and over the counter medicines. Its platform technology, known as Linguet™, enables the active ingredient of drugs to be absorbed straight into the bloodstream when placed inside the cheek (via the buccal mucosa) or under the tongue (sublingual).

"The expansion of our patent portfolio in both Japan, China and now Europe is a significant step in our commercialisation strategy. The US patent application is now the final major market we are working diligently on to attain global coverage," said Dr Nick Ede, Executive Director of Imugene.

- Ends -

**For investor enquiries please contact:**

**Dr Nick Ede, Imugene** – 0400 642 254 / [nede@imugene.com](mailto:nede@imugene.com)

### About Imugene

Imugene Limited (ASX:IMU) is commercialising drug delivery applications based on its novel buccal (drugs administered via the cheek) Linguet™ technology. Linguet™ is a patient friendly and cost effective system used to deliver established pharmaceutical and nutraceutical products.

For personal use only